About Us

Founded in 2014, Exactis Innovation (Exactis) is a Business-Led Networks Centres of Excellence (BL-NCE) that comprises a pan-Canadian Network of 16 oncology centers that brings together public and private partners focusing on precision oncology research.

Our Approach to Precision Oncology

PMT animation

What We Do

Personalize my Treatment (PMT) is an active pan-Canadian longitudinal cancer patient registry comprised of clinical and molecular data.

Exactis’ Clinical & Translational Operations team has proven experience in developing and managing longitudinal biomarker-based clinical trials and translational research.

Through our 16 site Network and PMT registry, our program for real-world effectiveness in precision oncology enables the assessment of cancer sub-populations in the real-world setting.

Ethical Commitment

Exactis is committed to conducting its activities with the highest ethical and professional standards to ensure respectful treatment of patients and all stakeholders, this includes respecting the rights and privacy of patients, ethical standards and regulatory requirements.

Our Values

  • Integrity
  • Patient-focused
  • Innovation
  • Collaboration
  • Inclusiveness
  • Performance-driven

Vision & Mission

Our Vision: “To empower healthcare stakeholders to improve cancer survivorship through timely, real world data-driven insights.”


Our Mission: “To accelerate precision oncology by integrating molecular and clinical patient profiles into innovative clinical and translational projects”.

Investigators’ / Sponsor’s Insights

  • We have been working with Exactis over the last two years to launch and support our multicenter pediatric study. The Exactis Team provides invaluable support for regulatory matters, monitoring and data management. They are always available, efficient and dedicated. There is no doubt we will continue our collaboration with Exactis for our upcoming studies.

    Dr. Sébastien Perreault M.D, FRCPC
    Clinicien-chercheur, Neurologie pédiatrique, Neuro-oncologie UCNS, CHU Sainte-Justine
  • Sermonix is honored to collaborate with Exactis Innovation, a truly esteemed international center of excellence in precision medicine,” said David Portman, Sermonix founder and chief executive officer. “Our ELAINE trials are solely focused on women with ESR1 mutations, for whom there is such great need of targeted treatments that potentially can prolong and enhance their lives. Working with Exactis furthers that mission.

    Dr. David Portman M.D
    Founder and CEO of Sermonix Pharmaceuticals